This site is intended for healthcare professionals

Light blue bubbles

Discontinued drug

New drug name(14)(16)(25)

Read time: 1 mins

Last updated:21st Sep 2020

Alternative approved drugs and related content

Blue test tubes arranged in a line, disappearing into the background

Blincyto + chemo boosts survival in pediatric B-ALL

3 mins

Blue test tubes arranged in a line, disappearing into the background

ENERGIZE-T: Positive results for mitapivat in thalassemia

3 mins

Blue test tubes arranged in a line, disappearing into the background

TEMPO-2: Positive results for tavapadon in early Parkinson's

3 mins

Blue test tubes arranged in a line, disappearing into the background

KEYLYNK-001: Keytruda + chemo, Lynparza for BRCA ovarian cancer.

1 mins

Systematic review-based guideline “Parkinson’s disease” of the German Society of Neurology: diagnostic use of transcranial sonography

1 mins

Guideline “Parkinson’s disease” of the German Society of Neurology (Deutsche Gesellschaft für Neurologie): concepts of care

1 mins

Diagnostics and treatment of impulse control disorders, psychosis and delirium: systemic review-based recommendations - guideline “Parkinson’s disease” of the German Society of Neurology

1 mins

German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson’s disease: new spotlights on diagnostic procedures and non-pharmacological interventions

1 mins

Pharmacotherapy of motor symptoms in early and mid-stage Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of Neurology

1 mins

Physical therapist management of Parkinson Disease: A clinical practice guideline from the American Physical Therapy Association

1 mins

European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies

2 mins

Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023

1 mins

Blue test tubes arranged in a line, disappearing into the background

Phase III data: ACCESS-1 trial of pozelimab + cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria

4 mins

Blue test tubes arranged in a line, disappearing into the background

Longer term results from phase IIIASC4FIRST trial with Scemblix (asciminib) showing superior major molecular response (MMR) rates at week 96

1 mins

Migraine treatment: Position paper of the French Headache Society

1 mins

International Headache Society global practice recommendations for preventive pharmacological treatment of migraine

1 mins

International Headache Society global practice recommendations for the acute pharmacological treatment of migraine

1 mins

Blue test tubes arranged in a line, disappearing into the background

Long term data from ongoing X-TOLE open-label extension (OLE) study of azetukalner in patients with focal onset seizures.- Xenon Pharmaceuticals

4 mins

Blue test tubes arranged in a line, disappearing into the background

Results from phase III POD1UM-304 trial of Zynyz ( retifanlimab ) + chemotherapy in NSCLC.- Incyte Inc.

2 mins

Blue test tubes arranged in a line, disappearing into the background

Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR- Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis- Daiichi Sankyo

2 mins